Ventricular assist devices market size was valued at $1,338.53 million in 2021, and is projected to reach $2,880.66 million by 2031, growing at a CAGR of 7.9% from 2022 to 2031. Ventricular assist devices market analysis provided from 2021 to 2031 to identify the prevailing market opportunities. Major factors that drive the growth of ventricular assist devices include the increase in prevalence of heart failure, technological advancements in the field of medical devices, and surge in patient awareness about ventricular assist devices.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Abbott Laboratories, AdjuCor GmbH, Corewave SA, Windmill Cardiovascular Systems, Berlin Heart GmbH, LivaNova PLC, Fineheart, Calon Cardio-Technology Ltd, Carmat SA, NuPulseCV, Inc., Bivacor Inc., Jarvik Heart, Inc., CH Biomedical, Inc., Evaheart, Inc., SynCardia Systems, LLC, Abiomed, Inc.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/2024
On the basis of product, the ventricular assist devices industry is classified into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). The left ventricular assist devices (LVADs) segment dominated the ventricular assist devices market in the year 2021. This increase in adoption of Left Ventricular Assist Devices (LVADs) is mainly attributed as it is used more commonly than Right Ventricular Assist Devices (RVADs) for several reasons such as the left ventricle is the main pumping chamber of the heart and providing support to the left ventricle can have a significant impact on overall heart function. Furthermore, heart failure is typically caused by dysfunction in the left ventricle, so LVAD can address the root cause of the condition. LVADs have been available and in use for longer than RVADs, due to their safety and efficacy.
On the basis of application, the ventricular assist devices industry is categorized bridge-to-transplant (BTT), destination therapy, bridge-to-recovery (BTR), and bridge to candidacy therapy. The bridge-to-transplant (BTT) segment exhibited the highest growth in 2021, owing to the rise in awareness among people regarding bridge-to-transplant therapy, which has significantly increased the success rate of transplant surgeries. On the other hand, destination therapy segment is anticipated to grow at a high rate during the forecast period as VADs have become a prominent solution for people with heart failure and for those who are ineligible for heart transplantation.
On the basis of design, the market is segmented into transcutaneous ventricular assist devices and implantable ventricular assist devices. The implantable ventricular assist devices segment held the largest share of revenue in 2021 and is anticipated to grow at a fastest CAGR rate during the forecast period. This growth is attributed to the technological advancements in the field of VADs and rise in research activities to develop efficient and high quality implantable ventricular assist devices.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/2024
Region wise, North America obtained the highest market share in 2021, whereas Asia-Pacific is expected to witness highest growth during the forecast period. In North America, rise in prevalence of heart failure, high adoption of technologically advanced ventricular assist devices, developed healthcare infrastructure, and increase in patient awareness about the availability of treatment options for heart failure are boosting the ventricular assist devices market share. In Asia-Pacific,ย growth is supplemented by surge in demand for sophisticated ventricular assist devices, large number of healthcare reforms, high prevalence of cardiac disorders, and increase in focus of key players to develop technologically advanced & cost-effective devices.
๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐๐:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on โStrategic Developmentsโ registered by leading players of the market
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com